Chimeric Antigen Receptor-modified T Cells Against Blood Malignant Tumor

To investigate whether the CD19 and CD138 chimeric antigen receptor(CD19/138-CAR) modified T cells can improve the killing efficacy to CD19+ mantle cell lymphoma cells and CD138+ Multiple myeloma cells,comparing to the non-genetically modified T cells. First, CD19/CD138-CAR fragment was constructed by PCR method, then the CD19/CD138-CAR fragment was cloned into a new generation of lentiviral vector. After recombinant lentivirus was prepared,T cells was transduced by CD19/CD138-CAR lentivirus. The CD19/CD138-CAR expression in the transduced T cells was detected by PCR, Western blot, and flow cytometryrespectively. Finally, cytotoxicity assay was performed to examine CD19/CD138-CAR-T cells to mantle cell lymphoma cells and CD138+ Multiple myeloma cells. The result showed that CD19/CD138-CAR-T cells can significantly improve cytotoxicity efficiency against CD19/CD138-positive tumor cells comparing with non-genetically modified T cells, suggesting the potential of CAR-T in immunotherapy clinically. To get a subset of central memory T cell which produced greater antitumor activity and long term persisitence in vivo,CAR-T cells were stimulated with Persongen aAPC and IL-7.